[
    [
        {
            "time": "2021-01-07",
            "original_text": "贝达药业(300558.SZ)提名童佳为非独立董事候选人",
            "features": {
                "keywords": [
                    "贝达药业",
                    "童佳",
                    "非独立董事",
                    "候选人"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)提名童佳为非独立董事候选人",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-01-07",
            "original_text": "贝达药业：为提高资金使用效率 拟使用不超8亿元暂时闲置募集资金进行现金管理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "资金使用效率",
                    "闲置募集资金",
                    "现金管理"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：为提高资金使用效率 拟使用不超8亿元暂时闲置募集资金进行现金管理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-01-07",
            "original_text": "贝达药业：拟发行H股并申请在香港联交所主板挂牌上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "香港联交所",
                    "主板上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：拟发行H股并申请在香港联交所主板挂牌上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-01-07",
            "original_text": "贝达药业拟发行H股并申请在港交所主板上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "港交所",
                    "主板上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业拟发行H股并申请在港交所主板上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-01-07",
            "original_text": "贝达药业(300558.SZ)：预计2021年日常关联交易总额不超5000万元",
            "features": {
                "keywords": [
                    "贝达药业",
                    "关联交易",
                    "总额",
                    "5000万元"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：预计2021年日常关联交易总额不超5000万元",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2021-01-07",
            "original_text": "贝达药业(300558.SZ)：拟用募集资金置换1.77亿元前期投入",
            "features": {
                "keywords": [
                    "贝达药业",
                    "募集资金",
                    "置换",
                    "1.77亿元"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：拟用募集资金置换1.77亿元前期投入",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-01-07",
            "original_text": "午间公告2021年1月7日星期四",
            "features": {
                "keywords": [
                    "午间公告",
                    "2021年1月7日",
                    "星期四"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "午间公告2021年1月7日星期四",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 2,
                "Time_Proximity": 4,
                "Headline_Structure": 3,
                "Source_Recency": 3
            }
        }
    ]
]